Comprehensive Stock Comparison
Compare C4 Therapeutics, Inc. (CCCC) vs Nurix Therapeutics, Inc. (NRIX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | NRIX | 54.0% revenue growth vs CCCC's -100.0% |
| Stability / Safety | NRIX | Beta 1.19 vs CCCC's 1.55, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | NRIX | +3.4% vs CCCC's -0.4% |
| Efficiency (ROA) | CCCC | -29.2% ROA vs NRIX's -38.4%, ROIC -36.9% vs -54.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degraders — a new class of medicines that eliminate disease-causing proteins rather than just inhibiting them. It generates revenue primarily through strategic collaborations and milestone payments from partners like Roche and Biogen, with future potential from drug royalties and product sales if its pipeline succeeds. The company's key advantage is its proprietary TORPEDO platform for designing selective protein degraders, which could offer better efficacy and safety than traditional inhibitors for challenging drug targets.
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies for cancer and immune disorders. It generates revenue primarily through strategic collaborations and licensing deals — including partnerships with Gilead Sciences and Sanofi — while advancing its own pipeline of oral BTK degraders and CBL-B inhibitors. The company's key advantage is its proprietary DELigase platform for discovering novel protein degraders, which could enable treatments for diseases that have been difficult to target with conventional small molecules.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
NRIX leads in 1 of 6 categories — strongest in Total Returns. 4 categories are tied.
Financial Metrics (TTM)
NRIX and CCCC operate at a comparable scale, with $84M and $0 in trailing revenue. On growth, NRIX holds the edge at +2.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CCCCC4 Therapeutics, … | NRIXNurix Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $84M |
| EBITDAEarnings before interest/tax | -$115M | -$267M |
| Net IncomeAfter-tax profit | -$105M | -$264M |
| Free Cash FlowCash after capex | -$99M | -$263M |
| Gross MarginGross profit ÷ Revenue | — | -87.4% |
| Operating MarginEBIT ÷ Revenue | — | -3.4% |
| Net MarginNet income ÷ Revenue | — | -3.1% |
| FCF MarginFCF ÷ Revenue | — | -3.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -5.8% | +2.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +81.6% | -9.3% |
Valuation Metrics
| Metric | CCCCC4 Therapeutics, … | NRIXNurix Therapeutic… |
|---|---|---|
| Market CapShares × price | $262M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $247M | $1.4B |
| Trailing P/EPrice ÷ TTM EPS | -2.13x | -5.24x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 19.36x |
| Price / BookPrice ÷ Book value/share | 0.87x | 2.57x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CCCC delivers a -40.9% return on equity — every $100 of shareholder capital generates $-41 in annual profit, vs $-49 for NRIX. NRIX carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to CCCC's 0.23x. On the Piotroski fundamental quality scale (0–9), NRIX scores 4/9 vs CCCC's 3/9, reflecting mixed financial health.
| Metric | CCCCC4 Therapeutics, … | NRIXNurix Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | -40.9% | -49.1% |
| ROA (TTM)Return on assets | -29.2% | -38.4% |
| ROICReturn on invested capital | -36.9% | -54.0% |
| ROCEReturn on capital employed | -36.6% | -48.6% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.23x | 0.10x |
| Net DebtTotal debt minus cash | -$15M | -$191M |
| Cash & Equiv.Liquid assets | $75M | $247M |
| Total DebtShort + long-term debt | $60M | $56M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in NRIX five years ago would be worth $4,406 today (with dividends reinvested), compared to $637 for CCCC. Over the past 12 months, NRIX leads with a +3.4% total return vs CCCC's -0.4%. The 3-year compound annual growth rate (CAGR) favors NRIX at 19.2% vs CCCC's -20.0% — a key indicator of consistent wealth creation.
| Metric | CCCCC4 Therapeutics, … | NRIXNurix Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | +39.9% | -11.6% |
| 1-Year ReturnPast 12 months | -0.4% | +3.4% |
| 3-Year ReturnCumulative with dividends | -48.8% | +69.4% |
| 5-Year ReturnCumulative with dividends | -93.6% | -55.9% |
| 10-Year ReturnCumulative with dividends | -89.4% | -16.0% |
| CAGR (3Y)Annualised 3-year return | -20.0% | +19.2% |
Risk & Volatility
NRIX is the less volatile stock with a 1.19 beta — it tends to amplify market swings less than CCCC's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | CCCCC4 Therapeutics, … | NRIXNurix Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.55x | 1.19x |
| 52-Week HighHighest price in past year | $3.65 | $22.50 |
| 52-Week LowLowest price in past year | $1.09 | $8.18 |
| % of 52W HighCurrent price vs 52-week peak | +74.0% | +71.0% |
| RSI (14)Momentum oscillator 0–100 | 76.0 | 45.3 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 946K |
Analyst Outlook
Wall Street rates CCCC as "Buy" and NRIX as "Buy". Consensus price targets imply 184.1% upside for CCCC (target: $8) vs 95.5% for NRIX (target: $31).
| Metric | CCCCC4 Therapeutics, … | NRIXNurix Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $7.67 | $31.22 |
| # AnalystsCovering analysts | 14 | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Oct 20 | Feb 26 | Change |
|---|---|---|---|
| C4 Therapeutics, In… (CCCC) | 100 | 7.38 | -92.6% |
| Nurix Therapeutics,… (NRIX) | 100 | 68.03 | -32.0% |
Nurix Therapeutics,… (NRIX) returned -56% over 5 years vs C4 Therapeutics, In… (CCCC)'s -94%.
Chart 2Revenue Growth — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| C4 Therapeutics, In… (CCCC) | $19M | $0.00 | -100.0% |
| Nurix Therapeutics,… (NRIX) | $37M | $84M | +124.3% |
C4 Therapeutics, Inc.'s revenue grew from $19M (2018) to $0M (2025) — a -100.0% CAGR. Nurix Therapeutics, Inc.'s revenue grew from $37M (2018) to $84M (2025) — a 12.2% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| C4 Therapeutics, In… (CCCC) | -81.1% | -3.0% | +96.4% |
| Nurix Therapeutics,… (NRIX) | -25.2% | -3.1% | +87.5% |
Nurix Therapeutics, Inc.'s net margin went from -25% (2018) to -3% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| C4 Therapeutics, In… (CCCC) | -1.06 | -1.27 | -19.8% |
| Nurix Therapeutics,… (NRIX) | -0.59 | -3.05 | -416.9% |
C4 Therapeutics, Inc.'s EPS grew from $-1.06 (2018) to $-1.27 (2025). Nurix Therapeutics, Inc.'s EPS grew from $-0.59 (2018) to $-3.05 (2025).
Chart 5Free Cash Flow — 5 Years
C4 Therapeutics, Inc. generated $-99M FCF in 2025 (-13% vs 2021). Nurix Therapeutics, Inc. generated $-263M FCF in 2025 (-193% vs 2021).
CCCC vs NRIX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is CCCC or NRIX a better buy right now?
Analysts rate C4 Therapeutics, Inc. (CCCC) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CCCC or NRIX?
Over the past 5 years, Nurix Therapeutics, Inc. (NRIX) delivered a total return of -55.9%, compared to -93.6% for C4 Therapeutics, Inc. (CCCC). A $10,000 investment in NRIX five years ago would be worth approximately $4K today (assuming dividends reinvested). Over 10 years, the gap is even starker: NRIX returned -16.0% versus CCCC's -89.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CCCC or NRIX?
By beta (market sensitivity over 5 years), Nurix Therapeutics, Inc. (NRIX) is the lower-risk stock at 1.19β versus C4 Therapeutics, Inc.'s 1.55β — meaning CCCC is approximately 30% more volatile than NRIX relative to the S&P 500. On balance sheet safety, Nurix Therapeutics, Inc. (NRIX) carries a lower debt/equity ratio of 10% versus 23% for C4 Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — CCCC or NRIX?
C4 Therapeutics, Inc. (CCCC) is the more profitable company, earning 0.0% net margin versus -314.9% for Nurix Therapeutics, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCCC leads at 0.0% versus -340.2% for NRIX. At the gross margin level — before operating expenses — NRIX leads at 77.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — CCCC or NRIX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is CCCC or NRIX better for a retirement portfolio?
For long-horizon retirement investors, Nurix Therapeutics, Inc. (NRIX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.19)). C4 Therapeutics, Inc. (CCCC) carries a higher beta of 1.55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NRIX: -16.0%, CCCC: -89.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between CCCC and NRIX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.